Department of Medical Biology, Medical University of Bialystok, Bialystok, Poland.
Department of Hygiene, Epidemiology and Metabolic Disorders, Medical University of Bialystok, Bialystok, Poland.
Biomed Pharmacother. 2024 Nov;180:117531. doi: 10.1016/j.biopha.2024.117531. Epub 2024 Oct 8.
Liver plays a central role in systemic glucose and lipid metabolism. High-fat diet (HFD) and obesity are related to hepatic lipid accumulation and insulin resistance (InsR). Diacylglycerols (DAG) play a key role in the induction of InsR, however their involvement in hepatic InsR remains debated. This study aimed to clarify and confirm the role of glycero-3-phosphate acyltransferase 1 (GPAT1), a rate-limiting enzyme in DAG synthesis, in the progression of hepatic InsR in the context of HFD-induced lipid accumulation and insulin resistance in the liver.
Liver-targeted GPAT1 silencing was performed using shRNA-mediated hydrodynamic gene delivery. Lipid species including LCA-CoA, sphingolipids, DAG and acyl-carnitines were quantified using UHPLC/MS/MS while insulin signalling was assessed at protein level by Western Blot. Hepatic glucose metabolism, including glucose-6-pasphate content and gluconeogenesis rate was evaluated using GC/MS.
HFD-fed animals developed InsR, evidenced by increased HOMA-IR, enhanced gluconeogenesis and reduced glycogen content compared to controls. Hepatic GPAT1 silencing in HFD-fed animals resulted in a significant reduction of DAG and TAG levels, increased acyl-carnitines content and upregulated mitochondrial β-oxidation protein expression. These changes were accompanied by improved insulin signalling, enhanced glycogen storage, and reduced gluconeogenesis.
Silencing GPAT1, and thereby reducing glycerolipid synthesis, promotes β-oxidation and ameliorates HFD-induced hepatic insulin resistance, confirming the enzyme's pivotal role in liver metabolic dysfunction associated with increased lipid supply.
肝脏在全身葡萄糖和脂质代谢中起着核心作用。高脂肪饮食(HFD)和肥胖与肝脂质积累和胰岛素抵抗(InsR)有关。二酰基甘油(DAG)在诱导 InsR 中起着关键作用,但其在肝 InsR 中的作用仍存在争议。本研究旨在阐明和证实甘油-3-磷酸酰基转移酶 1(GPAT1)在 HFD 诱导的脂质积累和肝脏胰岛素抵抗中,作为 DAG 合成的限速酶,在肝 InsR 进展中的作用。
使用 shRNA 介导的流体动力学基因传递来进行肝靶向 GPAT1 沉默。使用 UHPLC/MS/MS 定量包括 LCA-CoA、鞘脂、DAG 和酰基辅酶 A 在内的脂质种类,同时通过 Western Blot 评估胰岛素信号转导在蛋白质水平上的情况。使用 GC/MS 评估肝葡萄糖代谢,包括葡萄糖-6-磷酸含量和糖异生率。
HFD 喂养的动物出现 InsR,表现在与对照组相比,HOMA-IR 增加、糖异生增强和肝糖原含量降低。HFD 喂养的动物中肝 GPAT1 沉默导致 DAG 和 TAG 水平显著降低、酰基辅酶 A 含量增加和线粒体β-氧化蛋白表达上调。这些变化伴随着胰岛素信号转导增强、糖原储存增加和糖异生减少。
沉默 GPAT1,从而减少甘油脂质合成,促进β-氧化,并改善 HFD 诱导的肝胰岛素抵抗,证实了该酶在与增加脂质供应相关的肝脏代谢功能障碍中的关键作用。